Molindone for schizophrenia and severe mental illness

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Typical antipsychotics are first-line treatments for schizophrenia.
• Atypical antipsychotics are increasingly used due to favorable side effect profiles.
• Molindone, with low receptor binding, has been suggested as a safer alternative with atypical properties.

Purpose of the Study:

• To evaluate the efficacy and safety of molindone compared to placebo, typical, and atypical antipsychotics for schizophrenia and related psychoses.

Main Methods:

• Comprehensive electronic database searches were conducted from 1966 to 1999.
• Randomized controlled trials comparing molindone to other treatments were included.
• Data extraction and quality assessment were performed independently, with exclusion of studies with >50% loss to follow-up.

Main Results:

• Thirteen studies were included, with trial durations ranging from 10 days to over three months.
• Molindone showed no significant difference in effectiveness compared to typical antipsychotics.
• Molindone did not increase movement disorders but was associated with significantly more weight loss.

Conclusions:

• The evidence for molindone's efficacy and safety is limited by small sample sizes and study design.
• Molindone's adverse effect profile is comparable to typical antipsychotics, with the exception of weight gain.
• Currently, there is no evidence to classify molindone as an atypical antipsychotic.